secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000950170-24-089234
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus Q2 product revenue up 16% to $45M; raises FY2024 guidance to $175-178M
----------------------------------------------------------------------------

- Q2 product revenue $45.1M (+16% YoY); total revenue $50.5M (+6% YoY).
- GAAP net loss narrowed to $5.8M ($0.03/share) from $13.3M loss in Q2 2023.
- Non-GAAP adjusted EBITDA turned positive at $0.8M (vs -$4.7M prior year).
- Full-year product revenue guidance raised to $175-178M; IFC guidance unchanged at $8-10M.
- Canadian Blood Services achieved 100% INTERCEPT platelet adoption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000095017024089234/0000950170-24-089234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000095017024089234/cers-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-089234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer